Snapshot from Jul 26, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Elicio Therapeutics Securities Fraud...
Regulatory securities fraud investigation

Elicio Therapeutics Securities Fraud Investigation

Analysis based on 16 articles · First reported Jun 25, 2026 · Last updated Jun 29, 2026

Sentiment
-70
Attention
4
Articles
16
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market is negatively impacted by the significant drop in Elicio Therapeutics' stock price, reflecting investor concern over the failed clinical trial and potential securities fraud. This event could lead to increased scrutiny on other biotechnology companies' clinical trial disclosures and potentially affect investor confidence in the sector.

biotechnology legal services
Event Summary

Pomerantz LLP is investigating Elicio Therapeutics, Inc. for alleged securities fraud and unlawful business practices. This investigation follows a substantial drop in Elicio Therapeutics' stock price on June 15, 2026, after the company announced that its Phase 2 AMPLIFY-7P Study for ELI-002 7P in adjuvant pancreatic cancer did not meet its primary endpoint of disease-free survival. The stock fell by 70.96%, or $9.97 per share, closing at $4.08 per share. Pomerantz LLP is encouraging affected investors to contact them regarding potential class action lawsuits.

Key Actions
100 Pomerantz LLP investigating claims Elicio Therapeutics
95 Elicio Therapeutics stock price fell
90 Elicio Therapeutics issued press release
Entities Involved
stock
Elicio Therapeutics
Elicio Therapeutics is under investigation for potential securities fraud after its stock price plummeted due to negative clinical trial results for its ELI-002 7P drug. This event significantly impacts its reputation and financial standing.
Importance 100.0 Sentiment -90.0
priv
Pomerantz LLP
Pomerantz LLP is a law firm investigating Elicio Therapeutics for securities fraud on behalf of investors. This action is central to the event as they are leading the legal proceedings.
Importance 80.0 Sentiment 20.0
per
Danielle Peyton
Danielle Peyton is a contact person at Pomerantz LLP for investors interested in joining the class action against Elicio Therapeutics.
Importance 20.0 Sentiment 0.0
index
Nasdaq-100
Nasdaq-100 is the stock exchange where Elicio Therapeutics' shares are traded. The stock price drop occurred on this exchange.
Importance 10.0 Sentiment 0.0
Relationships
Pomerantz LLP related ↔ Danielle Peyton
Pomerantz LLP related ↔ Nasdaq-100
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.